Mandate

Vinge has advised Tobii in connection with the listing of Tobii Dynavox

Vinge has advised Tobii and Tobii Dynavox in connection with the distribution of the shares in Tobii Dynavox to the shareholders in Tobii as well as the listing of Tobii Dynavox’s ordinary shares on Nasdaq Stockholm. The prospectus was published 23 November 2021 and the first day of trading on Nasdaq Stockholm was 9 December 2021.

Tobii Dynavox is the global leader in assistive technology for communication. The company’s custom designed solutions enable people with disabilities such as cerebral palsy, ALS and spinal cord injury to communicate with a voice of their own, develop literacy skills and live more independently. To date, hundreds of thousands of people worldwide have benefited from their integrated solutions, which include hardware, software, clinically developed language systems, special education tools, training, and dedicated support. The company offers an extensive funding support system to reach as many people as possible. Headquartered in Sweden, Tobii Dynavox employs around 500 people with offices in the US, the UK, Norway and China, and reselling partners in 60+ countries.

Vinge’s team consisted of Jesper Schönbeck, Amanda Knutsson, Joel Magnusson, Emil Lindwall, Pernilla Björklund, Henrik Wastensson, Victor Ericsson and Emelie Svanberg,Maria Dahlin Kolvik, Christina Odengran, Ellinor Wargenbrant, Eléonore Friberg, Jolene Reimerson and Viktoria Owetz Leyva.

Related

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025